← Back to pipeline Science

Publications on CD39 and IPH5201

Selected publications and congress abstracts by the OREGA Biotech team and its academic and industrial partners.

2026

Clinical · Phase 2

Dual CD39 and PD-L1 inhibition: interim results from the phase 2 MATISSE trial of IPH5201 plus durvalumab and platinum-based chemotherapy in patients with resectable NSCLC

Barlesi et al. (plenary presentation, abstract CT231)

Cancer Research 2026;86(8_Suppl):CT231 · AACR abstract ↗

2025

Clinical · Phase 1

IPH5201, an anti-CD39 monoclonal antibody, as monotherapy or in combination with durvalumab in advanced solid tumors

Powderly J, Imbimbo M, Italiano A, Martin Romano P, McKean M, … Paturel C, Fraenkel PG, Hollebecque A

Cancer Research Communications 2025 (accepted manuscript) · doi:10.1158/2767-9764.CRC-25-0361 ↗

2024

Research

CD39 is expressed by a wide range of cutaneous T-cell lymphomas

Battesti et al.

Skin Health and Disease 2024;4(2):e334 · doi:10.1002/ski2.334 ↗

2022

Research

Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in Sézary syndrome

Sonigo et al.

Blood 2022;139(17):2712–2726 · Blood ↗

2020

Review

Une nouvelle génération d’immunothérapies ciblant la voie CD39/CD73/adénosine pour favoriser la réponse immunitaire anti-tumorale

Gros L, Paturel C, Perrot I, Bensussan A, Eliaou JF, Bastid J, Bonnefoy N

Médecine/Sciences 2020;36(2):112–115 · doi:10.1051/medsci/2020006 ↗

Research

Extracellular ATP and CD39 activate cAMP-mediated mitochondrial stress response to promote cytarabine resistance in acute myeloid leukemia

Aroua et al.

Cancer Discovery 2020;10(10):1544–1565 · doi:10.1158/2159-8290.CD-19-1008 ↗

2019

Research

Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies

Perrot I, Michaud HA, Giraudon-Paoli M, … Vivier E, Paturel C, Bonnefoy N

Cell Reports 2019;27(8):2411–2425 · doi:10.1016/j.celrep.2019.04.091 ↗

Research

Identification of CD39 as a marker for the circulating malignant T-cell clone of Sézary syndrome patients

Bensussan A, et al.

Journal of Investigative Dermatology 2019 · PubMed ↗

2016

Research

Regulatory T cells from colon cancer patients inhibit effector T-cell migration through an adenosine-dependent mechanism

Sundström P, Stenstad H, Langenes V, … Bastid J, Quiding-Järbrink M

Cancer Immunology Research 2016;4(3):183–193 · doi:10.1158/2326-6066.CIR-15-0050 ↗

AACR abstract

Preclinical development of a humanized blocking antibody targeting the CD39 immune checkpoint for cancer immunotherapy

Augier et al.

Cancer Research 2016;76(14_Suppl):3222 · AACR Annual Meeting 2016 · AACR abstract ↗

AACR abstract

Disruption of the CD39 immune checkpoint pathway increases the efficacy of various anticancer therapies in syngeneic mouse models

Lapierre et al.

Cancer Research 2016;76(14_Suppl):3218 · AACR Annual Meeting 2016 · AACR abstract ↗

2015

Review

CD39: a complementary target to immune checkpoints to counteract tumor-mediated immunosuppression

Bonnefoy N, Bastid J, Alberici G, Bensussan A, Eliaou JF

OncoImmunology 2015;4(5):e1003015 · doi:10.1080/2162402X.2014.1003015 ↗

2014

Research

Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity

Bastid J, Regairaz A, Bonnefoy N, Déjou C, Giustiniani J, … Alberici G, Bensussan A, Eliaou JF

Cancer Immunology Research 2015;3(3):254–265 (online Nov 2014) · doi:10.1158/2326-6066.CIR-14-0018 ↗

AACR abstract

Blockade of the CD39 immunoregulatory pathway by monoclonal antibodies

Bastid J, et al.

Cancer Research 2014;74(19_Suppl):5036 · AACR Annual Meeting 2014 · AACR abstract ↗

2013

Research

CD39 is involved in mediating suppression by Mycobacterium bovis BCG-activated human CD8+CD39+ regulatory T cells

Boer MC, van Meijgaarden KE, Bastid J, Ottenhoff THM, Joosten SA

European Journal of Immunology 2013;43(7):1925–1932 · doi:10.1002/eji.201243286 ↗

2012

Review

ENTPD1/CD39 is a promising therapeutic target in oncology

Bastid J, Cottalorda-Regairaz A, Alberici G, Bonnefoy N, Eliaou JF, Bensussan A

Oncogene 2013;32:1743–1751 (online Jul 2012) · doi:10.1038/onc.2012.269 ↗